Previous 10 | Next 10 |
AbbVie ( ABBV ) was able to obtain its first approval for SKYRIZI (risankizumab) in Japan for treating patients with psoriasis. This is good news, but the market opportunity in Japan is not better than that of the United States or Europe. It won't be long for potential U.S. approval at all...
CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the selection of new research for present...
Data supports M281’s potential to prevent placental transfer of disease-inducing antibodies from mother to fetus in alloimmune and autoimmune diseases of the fetus and newborn Global multi-center Phase 2 study of M281 in hemolytic disease of the fetus and newborn (HDF...
Momenta Pharmaceuticals (NASDAQ: MNTA ) initiated with Neutral rating at BTIG Research. More news on: Momenta Pharmaceuticals, Inc., Arcus Biosciences, Inc., Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Momenta Pharmaceuticals, Inc. (MNTA) Q4 2018 Earnings Conference Call February 22, 2019, 08:30 ET Company Participants Patty Eisenhaur - VP, Investor Relations and Corporate Communications Craig Wheeler - President, CEO & Executive Director Michelle Robertson - Principal Fina...
Momenta Pharmaceuticals ( MNTA ) Q4 results : Revenues: $42.8M (-33.7%); Product revenue: $10.8M (-19.4%); R&D revenue: $32.1M (-37.3%). More news on: Momenta Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Momenta Pharmaceuticals (NASDAQ: MNTA ): Q4 GAAP EPS of -$0.10 beats by $0.39 . More news on: Momenta Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Ended 2018 with a cash position of $449.0 million -- -- Phase 2 trials of M281 in myasthenia gravis (MG) and hemolytic disease of the fetus and newborn (HDFN) underway; First healthy volunteer dosed in Phase 1/2 trial of M254 in immune thrombocytopenia (ITP) -- CAMBRIDGE, M...
AN , ASIX , B , CNK , COG , COT , ERF , ETM , HMSY , ITT , MGA , MNTA , PNW , RCM , RUTH , RY , TDS , TVPT , USM , W , WPC For Seeking Alpha's full earnings season calendar, click here . More news on: AutoNation Inc, AdvanSix Inc., Barnes Group Inc, Earnings news...
Momenta Pharmaceuticals (NASDAQ: MNTA ) is scheduled to announce Q4 earnings results on Friday, February 22nd, before market open. The consensus EPS Estimate is -$0.49 (-372.2% Y/Y) and the consensus Revenue Estimate is $17.11M (-73.5% Y/Y). Over the last 2 years, MNTA has beaten EPS ...
News, Short Squeeze, Breakout and More Instantly...
Momenta Pharmaceuticals Inc. Company Name:
MNTA Stock Symbol:
NASDAQ Market:
Momenta Pharmaceuticals Inc. Website:
Are These Top 3 Pharmaceutical Stocks On Your October Watchlist? Investing in pharmaceutical stocks is a popular trend in times of political or economic instability. This is because the demand for drugs will still be steady all year long, no matter what is happening in the world...
Chesapeake Utilities to Join S&P SmallCap 600 Chesapeake Utilities to Join S&P SmallCap 600 PR Newswire NEW YORK, Sept. 25, 2020 NEW YORK , Sept. 25, 2020 /PRNewswire/ -- Chesapeake Utilities Corp (NYSE:CPK) will replace Momenta Pharmaceuticals In...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...